

Index

a

active immunoregulatory cytokine
IL-10 53

acute liver injury 54

acyl-homoserine lactone (AHL) 104,
200

adhesion mechanisms 122–124

adhesion modulation 125–126

AHR-mediated type I interferon
signaling 98

Akkermansia muciniphila 50

alanine dehydrogenase enzyme (AlaD)
55

allogenic stem cell transplantation
(alloSCT) 227

altered and aberrant microbiome
155

anchor-less elongation factor Tu
(EF-Tu) 124

5'-and 3'-untranslated regions (5'-and
3'-UTRs) 111

anhydrotetracycline (aTc) 164

anorexigenic lipids 208

anti-biofilm enzyme 178

antibiotics 201

anti-inflammatory bacterial taxa 223

anti-inflammatory interleukin-10
(IL-10) 53, 238

anti-inflammatory molecules 109,
243

antimicrobials 178, 201

antimicrobial screening systems 162

antimicrobial targets 162

antiseptic 4-hydroxybenzoic acid
164

aptamer domain 160

arabinooligosaccharides (AOS) 10

arabinose 163

aryl hydrogen carbon receptor (AHR)
97

autism spectrum disorder (ASD) 22,
63, 228, 243, 250

auto-phosphorylation reaction 290

auxotrophies 205

b

bacterial vaginosis (BV) 7

bacteriocin Pyocin S5 104

Bacteroides fragilis 14, 206, 289

Bacteroides thetaiotaomicron 9, 95,
99, 129, 155, 165, 206

bacteroidetes 97

Bacteroidetes/Firmicutes ratio 50

baker's yeast 168

bariatric surgery 227

Barker hypothesis 239, 240

basal metabolic rate (BMR) 13

bidirectional interaction 22, 155

Bifidobacterium longum 55

Bifidobacterium-rich microbiota 245

Bifidobacterium spp. 14, 50, 236, 251

bile-acid metabolism 226

bile salt hydrolases (BSH) 56

biofertilization 145

- bioinformatic initiatives 27
 - bioinoculants 145
 - biomarker discovery 159
 - biosensors, types of 159
 - engineering TCS-based sensors 167
 - GPCR 168
 - advances, in yeast 170–171
 - engineered, into yeast 168–170
 - gut microbiome 168
 - riboswitches 159
 - design and selection of, synthetic 160–161
 - molecular detection, of microbiome metabolites 161–162
 - regulatory mechanisms 160
 - TCS systems, for gut diagnostics 166–167
 - testing and utilizing engineered biosensors 171
 - CFPS 171–173
 - in vitro* testing 173–176
 - transcription factors 163
 - applications 165
 - engineering 164
 - mining 163–164
 - in vitro* testing 173
 - OOC 174
 - in vitro* host-microbe characterization 174–176
 - in vitro* models 174
 - biostimulation 145
 - biosynthesis pathway 200
 - biotherapeutic granulocyte
 - macrophage-colony stimulating factor (GM-CSF) 178
 - bottom-up approach 196
 - brain-gut axis (BGA) 224
 - brain-gut-microbiome (BGM) 22
 - Broad Institute OpenBiome Microbiome Library 159
 - broad-spectrum antibiotics 60, 224
- C**
- Caco2 cells 174
 - Caenorhabditis elegans* intestine 165
 - CAI-1-sensing two-component regulatory system (TCS) 105
 - Canadian Institutes of Health Research (CIHR) 27
 - Canadian Microbiome Initiative (CMI) 27
 - carbapenem-resistant *Enterobacteriaceae* 224
 - carbon catabolite repression 101
 - cardiometabolic risks 236
 - cardiovascular disease (CVD), microbiome engineering 58, 59
 - gut microbiome interventions 59–60
 - microbiome-derived TMAO 60–61
 - cardiovascular diseases 94
 - catecholamines 63
 - cell and mucus-binding protein A (CmbA) 124
 - cell-free protein expression systems (CFPS) 171–173
 - cell-surface protein Spr1345 123
 - central nervous system (CNS) 61
 - cheap paper-based system 173
 - chemotaxis signaling protein (CheZ) 162
 - chenodeoxycholic acid 57
 - Chinese hamster ovary (CHO) cells 172
 - chloramphenicol 201
 - cholera autoinducer 1 (CAI-1) 105
 - Clostridium clostridioforme* 50

- Clostridium difficile* infection (CDI) 18, 99, 105, 208, 220, 222
- coarse-grained ODE models 202
- colon epithelia 95
- colonizing bacteria 94
- colorectal microbiota 4
- commensals 93
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) 145
- communication molecules 201
- complex macromolecules 199
- complex plant-associated microbiomes 137
- coronary artery disease (CAD) 58
- corticotropin-releasing hormone (CRH) 249
- cortisol 155
- Corynebacterium glutamicum* 162
- CO₂-supplying butyrate oxidation 95
- COVID-19 pandemic 148, 220
- critical illness, of newborns 250
- Crohn's disease (CD) 20, 178, 223
- Cynomolgus monkeys 56, 292
- cytotoxic T-lymphocyte associated protein-4 (CTLA-4) 177
- d**
- deorphanization 170
- deoxycholic acids (DCA) 56
- design-build-test-learn (DBTL) 112, 138, 202, 209, 278
- dextranomer microspheres (DM) 127
- dextran sodium sulfate (DSS)-colitis mouse model (C57Bl/6) 290
- dextran sulfate sodium (DSS) 21, 98
- dietary lifestyle variation, affecting host microbiome 8
- age groups and dietary-related microbiome changes 13–15
- continental dietary difference
Africa 16
Asia 15
Australia 16
Europe 15–16
North America 17
South America 16
- dietary role, in shaping microbiome 8
dietary fibres 9–10
lipids 10–11
protein and polypeptides 8–9
soluble saccharides 9
- diet-related microbiome changes 11–13
- dietary modulation, of microbiome 17
- cancer 21–22
- infection 17
FMT 17–19
prebiotic-, diet- and probiotic-mediated prevention 19–20
- inflammatory disease 20–21
- psychological disease 22
ASD 22
neurodegenerative diseases 23
- dispersin B (DspB) 178
- distal organs 98
- DNA-editing all-in-one RNA-guided CRISPR-Cas Transposase (DART) method 145
- DNA polymerase (DNAP) 287
- downstream promoter-reporter system 109
- Dynamic Cyan Induction by Functional Integrated Receptors (DCyFIR) 170
- dynamic modelling 203
- dysbiosis 250

e

- E. coli* chemotaxis system 162
 - effector domain 166
 - Emulate Bio microfluidic device 175
 - endogenous ethanol 226
 - endometrial microbiota 234–236
 - engineered biosensing probiotics 179
 - engineered microbes 176
 - for disease diagnostics 176, 177
 - cancer 177–178
 - future translation 178–179
 - IBD 178
 - infection 178
 - identifying microbiome changes *in situ* 176
 - engineered probiotics 155, 156
 - engineering microbiome, to treat diseases
 - disease-related perturbations 103, 105, 106, 109, 110
 - strain selection for 102–103
 - therapeutic proteins 110–111
 - engineering population control 206–207
 - engineering synthetic consortia
 - analysis tools 202
 - cell-to-cell communication 200–201
 - computational models 202
 - agent-based models 203
 - dynamic/deterministic models 202–203
 - stoichiometric and genome-scale metabolic models 203–205
 - external and intercellular signal molecules 201
 - genetic manipulation tools 200
 - secretion and exchange, of metabolites 201–202
 - engineering syntrophy 205, 206
 - Enterobacter* 235
 - Enterococcus* 235
 - enteroendocrine L cells 50
 - environmental manipulation 141
 - environmental transformation
 - sequencing (ET-Seq) 145
 - episomal system 110
 - epithelial enterochromaffin cells 63
 - eukaryote riboswitches 160
 - European Society of Microbiology and Infectious Disease (ECMID) 222
 - extracellular polymeric substances (EPS) 127
 - extracytoplasmic function (ECF)
 - sigma factor 101
 - Extreme Science and Engineering Discovery Environment (XSEDE) 159
- f**
- Faecalibacterium prausnitzii* 11, 95, 227
 - farnesoid X receptor (FXR) signaling 226
 - fecal microbiome transplantation (FMT) 17–19, 52
 - fecal microbiota therapy
 - clinical application
 - C. difficile* infection 222–223
 - IBD 223–224
 - IBS 224–225
 - and liver diseases 225–226
 - and slow-transit constipation 225
 - therapeutic option 224
 - novel indications
 - autoimmune diseases 227
 - chemotherapy-induced diarrhea 226
 - GVHD 227
 - neuropsychiatric disorders 227–228
 - obesity and metabolic syndrome 227

- fecal microbiota transplantation
 (FMT) 219
 administration of 220
 potential donors, recruitment of
 220, 221
 safety 220, 222
- Firmicutes* 97
- Firmicutes/Bacteroides* 24
- Firmicutes/Bacteroidetes* ratio 16
- flavin-containing monooxygenase
 (FMO) enzyme 60
- 5-fluorouracil (FU) 125
- flux balance analysis (FBA) 144, 203
- FMT donor screening studies 221
- “focal” species *Pantoea* sp. YR343
 141
- formula feeding 240
- four-species consortium 206
- fructooligosaccharides (FOS) 10
- fulminant colonic inflammation 222
- fumarate and nitrate reductase (FNR)
 282
- functional encapsulations and biofilms
 126, 127
- g**
- galactooligosaccharides (GOS) 10,
 245
- γ -aminobutyric acid (GABA) 59, 63,
 155
- gastrointestinal inflammation 103
- gastrointestinal tract (GIT) 2, 122,
 223
- genetic enzyme screening system
 (GESS) 109
- genetic manipulation tools 200
- genome-scale levels 202
- genome-scale metabolic models
 (GEMs) 143–144, 203
- Gibson assembly 288
- glucagon-like peptide-1 (GLP-1) 50
- glucagon-like peptide-2 (GLP-2) 24
- gluten-and casein-free (GFCF) 22
- GM dysbiosis 219
- Golden Gate assembly system 288
- G protein-coupled receptors (GPCRs)
 159, 168
- G protein coupling 169
- graft-versus-host disease (GVHD)
 227
- green fluorescent protein (GFP)
 expression 141
- greenhouse gas emissions (GHGE)
 15
- gross domestic product (GDP) per
 capita 11
- gut-brain axis (GBA) 61
- gut ecosystem 111
- gut-inhabiting bacteria 93
- gut microbiota 219
- gut-on-a-chip *in vitro* models 174
- h**
- heat shock protein 65 (HSP65) 59
- hepatic *de novo* lipogenesis 226
- hepatic encephalopathy (HE) 54, 58,
 225
- hepatocellular carcinoma 57
- Herbaspirillum frisingense* 141
- heterologous protein 110, 198, 279,
 289
- high-affinity phenylalanine-specific
 permease (PheP) encoded
 110
- hospital-acquired infection 222
- host and microbial metabolites 47
- host-microbe interactions, of host
 metabolism 97–98
- host-microbial interactions 93, 102
- host-microbiome interactions 98
- host-microbiota interactions 168
- host phenotype modulation 175
- human disorders 94
- human gut 47
- human maternal gut microbiota
 epigenetic regulation 238–239

- human maternal gut microbiota
(*contd.*)
- gut and brain axis 238
 - maternal gut microbiome and immune functions 236–238
 - placental microbiome and meconium 239
- human maternal microbiota
- endometrial microbiota 234–236
 - gut microbiota 236
 - oral microbiota 233–234
 - vaginal microbiota 234
- human microbiome 173, 207, 208
- current approaches 7
- Human Microbiome Project (HMP) 2, 25
- human microbiota 93, 121, 168, 236
- human milk oligosaccharides (HMO) 245
- human milk microbiota and infant health 245–246
- Human Oral Microbiome Database (HOMD) 2
- hydroxypropyl-methylcellulose (HPMC)-based buccal films 127
- hyperammonemia 54, 55
- hypercholesterolemia 56
- hyperglycemic mice model 24
- hypothalamic-pituitary-adrenal (HPA) 249
- hypoxic tumor microenvironment 177
- i**
- immune cell polarization 237
 - immune impairment 98
 - immunomodulatory molecules 97
 - induced pluripotent stem cells (iPSC) 174
 - inducible promoter 104
 - inflammatory bowel disease (IBD) 18, 20, 94, 178, 223, 247
 - ingestible micro-bio-electronic device (IMBED) 165
 - immune checkpoint inhibitor (ICI)-induced colitis 226
 - insulin resistance 18
 - interdisciplinary research 142
 - interleukin-17 (IL-17) 238
 - interleukin-22 (IL-22) 97
 - International Diabetes Federation (IDF) 49
 - International Human Microbiome Consortium (IHMC) 25
 - intestinal indole-3-aldehyde 98
 - intestinal metabolic landscape 97
 - intestinal mucosal permeability 24
 - intratumoral antigen-presenting cells (APC) 177
 - in type II diabetes (T2D) patients 24
 - in vitro* screening 176
 - irritable bowel syndrome (IBS) 224
 - isolated microorganisms 157
 - isopropyl β -D-thiogalactopyranoside (IPTG) 156
 - isopropyl β -D-1-thiogalactopyranoside (IPTG) 279
 - isopropyl- β -D-thiogalactoside (IPTG) 163
- k**
- Klebsiella* 8, 244, 250
 - Kruppel-like factor 4 95
 - kynurenic acid 63
- l**
- lactic acid 242
 - lactic acid bacteria (LAB) 121
 - lactic acid-producing *Lactobacillus* species 234
 - Lactobacillus* 50
 - Lactobacillus rhamnosus* 54

- Lactobacillus rhamnosus* GG (LGG) 59
- Lactococcus lactis* 167
- Lactococcus lactis*-based recombinant interleukin-10 expression system 109
- L-amino acid deaminase (LAAD) 56, 110, 285
- layered genetic circuits 285, 286
- L-carnitine 60
- left ventricular ejection fraction 59
- ligand screening 170
- ligase chain reaction (LCR) 287
- limit energy absorption 24
- linear discriminant analysis effect size (LEfSe) 157
- lipopolysaccharide (LPS) 24
- liquid chromatography-mass spectrometry (LC-MS) 157
- liquid nitrogen 158
- live biotherapeutic products (LBP) 65, 74
- liver cirrhosis 54
- low-density lipoprotein receptor-deficient (LDL-RD) murine model 59
- lower limit of quantification (LLOQ) 175
- lysine-OFF riboswitch 162
- m**
- malleable microbiome 155
- Marionette strains 165
- maternal microbiota and gestational age 243, 244 and health 240 and obesity BMI 241 childhood and obesity 241 insulin resistance 241 maternal diet 240–241 miscarriages and microbiome 242 obesity 241 membrane-bound histidine kinase (HK) 283 metabolic disorders 23, 94 diabetes 24 NAFLD 24–25 obesity 23–24 metabolic dysfunction 98 metabolic engineering 128–129 metabolic endotoxemia 226 metabolic modelling 196 metabolomics 156 metagenome-assembled genomes (MAGs) 157 metagenome-wide association studies (MGWAS) 49 metagenomics 156–157 METAgenomics of the Human Intestinal Tract (MetaHIT) 26 metatranscriptomics 156–157 metatranscriptomics studies 142 methotrexate (MTX) 125 microbe-microbe interactions 97 microbes and compositions, host metabolic status 95, 97 microbial-based diagnostics 168 microbial-derived riboflavin metabolites, interferon-7 238 microbial diagnostics 107 microbial fermentation 10 microbial fingerprinting 219 microbially imbalanced intestine 96 microbial metabolism 102 microbial residents 93 microbiome compositions 102 microbiome development, elements for 5 diet and nutrition 7 prebiotics 6

- microbiome development, elements for (*contd.*)
 - probiotics 6–7
 - microbiome, diagnosing
 - considerations and future 158–159
 - microbiome analyses
 - metagenomics 157
 - metatranscriptomics 157
 - proteomics and metabolomics 157–158
 - small subunit rRNA analysis 156–157
 - microbiome diversity, in human body
 - gastrointestinal microbiome 3–4
 - oral microbiome 2–3
 - respiratory microbiome 5
 - skin microbiome 4–5
 - urogenital microbiome 5
 - microbiome engineering
 - for diabetes and obesity 49–50, 52
 - for immune modulation 52–53
 - modulate gut-brain axis 61–63
 - psychobiotics, development of 64–65
 - for modulate gut-liver axis 54
 - modulate ammonia metabolism 54–56
 - modulate bile salt metabolism 56–58
 - for next-generation precision agriculture 137–138
 - computational tools, for robust microbiome engineering 142–143
 - genome-scale metabolic modeling 143–144
 - systems approach 139–142
 - microbiome-mediated dysregulation 61
 - microbiome project supporting
 - infrastructures 25
 - global foundations 27
 - international and local initiatives 25–27
 - microbiome therapeutics 102
 - microbiota 1
 - microfluidic devices 174
 - Million Microbiome of Humans Project (MMHP) 26
 - mitigation strategies 146
 - mitogen-activated protein kinase (MAPK) 169
 - mixed co-cultures 174
 - mucin glycoproteins 123
 - mucosa-associated invariant T cells (MAIT) 238
 - mucus-associated surface proteins 126
 - mucus-binding factor (MBF) 124
 - mucus-binding (MUB) protein 123
 - multi-drug resistant organisms (MDRO) 224
 - multi-input/multi-output strain 165
 - multi-omics 159
 - multiple drug-resistant organisms (MDRO) 219
 - multiple logic gate circuits 165
 - multiple sclerosis 219
 - multi-species probiotic formulations 52
- n**
- N*-acetyl-D-glucosamine 101
 - N*-acyl homoserine lactone (AHL) 156
 - natural cell-to-cell communication systems 201
 - natural consortia 196
 - neurodegenerative diseases 23
 - neurodevelopment disorder 22
 - neuroendocrine 61
 - neurohumoral signaling 121
 - neuroimmune system 61
 - neuropsychiatric disorders 227, 228
 - nitrate (NO₃⁻) 106

- nitric oxide (NO) 178
N-methyl-*D*-aspartate (NMDA)
 receptor 63
 non-alcoholic fatty liver disease
 (NAFLD) 23–25, 225
 norepinephrine 63
 Novozymes 146
- O**
- OFF switch 160, 162
 oligonucleotides 287, 288
 oligosaccharides 14, 245, 247
 omics 156
 one-component regulatory systems
 (OCSs) 283, 284
 oral cavity species 233
 ordinary differential equations (ODE)
 202
 organic incubator 93
 organoids 174
 organ-on-a-chip (OOC) platforms
 174
 oropharynx microbiota 250
 outer membrane vesicles (OMV) 99,
 289
 output modules, types of 284, 285
- P**
- pancreatic β cell death 53
 Parkinson's disease 22, 23, 219, 227,
 238
 pathogenic bacteria 94, 103, 234,
 246, 250, 283, 285
 perinatal antibiotic treatment
 247–249
 peripheral regulatory T cells 95
 personalized nutrition 235
 personalized probiotics 235
 pharmacodynamics (PD) 74
 pharmacokinetics (PK) 74
 phase-variable surface layers 99
 phenylalanine ammonia-lyase (PAL)
 110, 284
 phenylalanine hydroxylase (PAH)
 55, 110
 phenylalanine lyase (PAL) 56
 phenylketonuria (PKU) 56, 284
 phenylpyruvate (PP) 292
 phosphotransfer 166
 phosphotransferase system (PTS)
 transporter 128
 phylogenetic lineages 157
 phytobiomes 146
Pimelobacter simplex 164
 plant growth-promoting (PGP) traits
 139
 point-of-care sensing 172
 polymerase chain reaction (PCR)
 287
 polymerase cycling assembly (PCA)
 287
Populus deltoides 141
Porphyromonadaceae 54
 postpartum microbiome
 mode of, delivery 242–243
 vaginal seeding 243
 Precigen ActoBio 53
 probiotic and prebiotic therapies as
 modulators 250–251
 probiotic-associated therapeutic curli
 hybrids (PATCH) system
 127
 probiotic engineering 155
 probiotics, and mechanism of action
 clinical studies 71–73
 preclinical studies 66–70
 programmed cell death protein-ligand
 1 (PD-L1) 177
 proinflammatory cytokines 103, 223
proteobacteria 243
 proteomics 156
 proton pump inhibitors (PPI) 222
Pseudomonas aeruginosa 104, 165,
 283
Pseudomonas proliferation 250
Pseudomonas syringae 164

- putative mucoadhesion factors 125
 pyrimido[4,5-d]pyrimidine-2,4-diamine (PPDA) 162
- q**
- quinolinic acid 63
 quorum-sensing circuit 165, 177
 quorum-sensing molecules 105, 156, 165, 200, 207
- r**
- Raman microspectroscopy 141
 randomized genome-wide disruption 100
 reactive oxygen species (ROS) 106
 recommended dietary allowances (RDA) 15
 respiratory microbiome 5
 response regulator (RR) 166, 283
 reverse transcriptase-quantitative PCR (RT-qPCR) measurements 173
 rhamnose 156
Rhodopseudomonas palustris 206
 ribosome binding site (RBS) 160, 289
 riboswitch engineering 160
 RNA-based regulatory systems 159
 RNA polymerase (RNAP) 278
 RNA sequencing approaches 157
 routine colonoscopy 220
- s**
- saccharolytic commensal B 101
 S-adenosylmethionine 161
Salmonella typhimurium 106, 167, 206
 “self-established, metabolically cooperating yeast community” (SeMeCo) 205
 semi-synthetic consortia 196
 sensor histidine kinase (SK) 166
 sensor optimization approaches 176
 serotonergic neurotransmission 63
Shewanella halifaxensis 167
 short-chain fatty acids (SCFAs) 10, 20, 50, 95, 237, 238
 short-fatty acid metabolism 96
 Singapore Research, Innovation and Enterprise Council (RIEC) 148
 skin microbiota 5
 small intestinal bacterial overgrowth (SIBO) 225
 small intestinal secretory immunoglobulin A (IgA) 123
 small subunit rRNA (SSU rRNA) 157
 smoking 249
 spatio-temporal pattern generators 207
 16S rRNA sequencing 105
 Ste12-responsive genes 170
 STimulator of INterferon Genes (STING) 177
 streptozotocin-induced T1D mice model 53
 stress under pregnancy 249, 250
 synthetic biology 195
 for genome and genetic engineering 144–146
 synthetic communities (SynComs) 139
 synthetic microbial consortia 207, 208
 advantages of, labor division 197
 metabolic burden 198–199
 optimal conditions 198
 reducing crosstalk and competition 199–200
 synthetic transcription factors (STFs) 170
 systematic evolution of ligands by exponential enrichment (SELEX) 161

- systems biology 102
 high-throughput data-driven, of gut microbiota 100–101
 rational design of, gut microbiome editing strategies 98–100
- t**
- T-cells within colonic mucosa 226
- terminators 111
- tetracycline 164, 201
- tetrathionate 106, 167
- tetrathionate/thiosulfate 109
- TF-based biosensors
 chasis 288–289
 construction of, genetic circuits 286
 construction of, genetic circuits gene synthesis 287
 Gibson assembly 288
 restriction enzyme-based cloning 287–288
 construction of, genetic circuits Gibson assembly 288
 strategies, for improvement 293
- test
 biocontainment 292–293
 diagnostics 289–290
 therapeutics 291–292
- transcriptional activators 282–283
- transcriptional repressors 278–279, 282
- The Environmental Determinants of Diabetes in the Young (TEDDY) 2
- T-helper cells 97
- The Microsetta Initiative (TMI) 26
- thorough-omics profiling 196
- toehold switches 160, 172
- toll-like receptors (TLRs) 226, 237, 238
- top-down approaches 197
- trans-cinnamic acid 56
- transcriptional activator 164
- transcription factor (TF)
 based biosensors 280
 based single-cell genetic reporter system 109
- transepithelial electrical resistance (TEER) measurements 175
- transposon insertion sequencing (Tn-Seq) 100, 105
- transposon mutagenesis sequencing (Tn-Seq) 100
- Transwell dishes 174
- trimethylamine (TMA) 60
- trimethylamine N-oxide (TMAO) 60
- tryptophan-2,3-dioxygenase (TDO) 63
- tryptophan metabolism 63, 95
- two-component histidine kinase receptor CqsS 105
- two-component regulatory systems (TCSs) 283
- two-component systems (TCSs) 159, 166–167
- type 1 diabetes (T1D) 49, 227
- type 2 diabetes (T2D) 49
- Typhimurium 96
- tyrosine-kinase inhibitors (TKIs) 226
- u**
- ulcerative colitis (UC) 20, 178, 223
- undesired downstream gene expression 169
- unmanned aerial vehicles (UAVs) 147
- UN Sustainable Development Goals (SDG) 147
- 5'-untranslated region (UTR) 111, 160, 292
- uric acid 164

urogenital microbiome 5
US National Institutes of Health
(NIH) 2

V

vaginal microbiota 234, 235, 242
vancomycin-resistant *Enterococcus*
(VRE) 224
very low birth weight (VLBW) infants
243
very-low-density lipoprotein (VLDL)
226
Vibrio cholerae 165, 167
visual reporter (lycopene) 170

W

wastewater treatment 140, 141
wild type bacteria 52
Wisconsin Alumni Research
Foundation (WARF) 27
World Economic Forum (WEF) 147

X

xylooligosaccharides (XOS) 10

Y

yeast G-protein machinery 169
yield biochemicals 95

